TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer (NSCLC). However, effective stratification factors for immunotherapy remain unclear. The purpose of this study was to discuss t...

Full description

Bibliographic Details
Main Authors: Jun Lu, Runbo Zhong, Yuqing Lou, Minjuan Hu, Zhengyu Yang, Yanan Wang, Ya Chen, Benkun Zou, Wei Zhang, Huimin Wang, Baohui Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
immunotherapy
biomarker
TP53 mutation
source of tissue
non-small-cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.732125/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.732125/full

Similar Items